Operator

Good evening, and welcome, everyone, to tonight's webinar event. Before we begin, just a few reminders to anyone who is new to the webinar. [Operator Instructions]

We would like to thank CyPath Lung for sponsoring this webinar and 2026 SAB sponsors. At this time, I will hand it over to Dr. Sussman, who will be moderating tonight's session. Thank you for joining.

Robert Sussman

Thank you, and good evening, everybody. Thanks for joining us for this program. And I'd especially like to thank the Society for Advanced Bronchoscopy for hosting this webinar. We're very lucky today we have an excellent multidisciplinary panel, including an interventional pulmonologist, a thoracic surgeon and an oncologist who are really at the forefront of diagnosis and treatment of lung cancer.

My name is Robert Sussman. I'll be your moderator for today's program. I practiced pulmonary for 37 years at Atlantic Health System in Summit, New Jersey. I recently retired from clinical practice. During my time in practice, I also was the Medical Director of the Atlantic Health System Pulmonary Clinical Research Center. That's where I first became aware and involved with CyPath Lung testing, which is what we're here to talk about today. I was a principal investigator in several of their trials and a co-author on 2 of their papers.

Tonight, we'll discuss how this noninvasive test can really be used to help stratify indeterminate lung nodules. You'll hear how this test can be used to give you greater precision in risk stratification and diagnosis. Let me just ask the panel to introduce themselves and their practices. Dr. Guda, we will